Agencia Europea de Medicamentos. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy GINA step 4 treatment: External validity of randomized controlled trials in asthma: Omalizumab for asthma in adults and children.
Cochrane Database Syst Rev. Anti-IgE for chronic asthma in adults and children. Principal findings of systematic reviews for chronic pharmacologic treatment in childhood asthma. National Asthma Education and Prevention Program.
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: National Institutes of Health. Predicting and evaluating response to omalizumab in patients with severe allergic asthma.
J Allergy Clin Immunol. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Persistency of response to omalizumab therapy in severe allergic IgE-mediated asthma. Effectiveness of omalizumab Xolair in the first patients treated in real-life practice in France. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Real life effectiveness of omalizumab in patients with severe persistent allergic asthma: Italian real life experience of omalizumab.
Omalizumab Therapy in Severe Asthma: Therapy with omalizumab in patients with severe persistent allergic asthma: Therapeutic effect of omalizumab on 10 patients with severe persistent asthma. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real life study of three years omalizumab in patients with difficult-to-control asthma.
Longitudinal changes in asthma control with Omalizumab: Omalizumab in patients with severe asthma: Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
Effectiveness of omalizumab in severe allergic asthma: Omalizumab management beyond clinical trials: Population-based assessment of adverse events associated with long-term glucocorticoid use. Corticosteroid-induced clinical adverse events: The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.
Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting.
Allergy Asthma Clin Immunol. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Response of older patients with IgE-mediated asthma to omalizumab: Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
Exploring the effects of omalizumab in allergic asthma: Lowe PJ, Renard D. Br J Clin Pharmacol. Effects of Omalizumab in non-atopic asthma: A proof of concept, randomized, controlled trial of omalizumab in patients, with severe, difficult-to-control nonatopic asthma. Efficacy of omalizumab in the treatment of nasal polyps. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
Effects of omalizumab in Aspergillus-associated airways disease. Allergic bronchopulmonary aspergillosis and omalizumab. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. After 6 years with Xolair; a 3-year withdrawal follow-up. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Loss of asthma control after cessation of omalizumab treatment: Servicio de ayuda de la revista.
Referencias Agencia Europea de Medicamentos.